RxDoctor Payments Data

Alexis Sokil, MD

Cardiovascular Disease · Philadelphia, PANPI 1689694440

Payments from drug & device makers

$1,674in general payments, 2019–2025

Across 98 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$247
  • E.r. Squibb & Sons, L.L.C.$224
  • Pfizer$201
  • Boehringer Ingelheim$174
  • Novartis$90
  • Impulse Dynamics (USA) Inc.$86
  • plus $652 from 19 others

What the payments were for

  • Food & beverage$1,66099%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,674 in reported general payments places this provider in the 45th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$93,993
Medicare patients
440
Services billed
993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$132,072
EntrestoSacubitril/Valsartan32$51,064
XareltoRivaroxaban23$14,675
Atorvastatin Calcium200$3,123
Metoprolol Succinate140$2,486
Rosuvastatin Calcium90$2,196
Disopyramide Phosphate13$2,023
Amiodarone Hcl23$1,281
Carvedilol61$1,186
Losartan Potassium50$1,143
ClopidogrelClopidogrel Bisulfate47$968
Amlodipine Besylate62$813
Ezetimibe32$797
Midodrine Hcl13$581
Lisinopril42$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$201$132,072100 claims
NovartisEntresto$90$51,06432 claims
Johnson & JohnsonXarelto$86$14,67523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →